Related Experiment Videos
Urapidil in hypercholesterolemic hypertensive patients
L A Ferrara1, G Leonetti, R Fogari
1Institute of Internal Medicine, Federico II University, Naples, Italy.
Insights
Urapidil effectively lowered blood pressure (BP) in hypertensive patients with hypercholesterolemia. This study found urapidil to be a safe and effective treatment option for managing both conditions simultaneously.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Arterial hypertension and hyperlipidemia significantly increase cardiovascular disease risk.
- Some antihypertensive drugs may positively impact lipid profiles.
Purpose of the Study:
- To evaluate the effects of urapidil on blood pressure and plasma lipids in hypertensive patients with hypercholesterolemia.
- To compare urapidil's efficacy against a placebo over six months.
Main Methods:
- A double-blind, randomized study involving 49 patients with mild hypertension and hypercholesterolemia.
- Patients were treated with either urapidil or a placebo for six months.
- Blood pressure and serum lipid levels were monitored throughout the study.
Main Results:
- Urapidil significantly decreased blood pressure from 159/99 mmHg to 152/90 mmHg.
- No significant change in blood pressure was observed in the placebo group.
- The difference in blood pressure reduction between the urapidil and placebo groups was statistically significant (p < 0.05).
Conclusions:
- Urapidil demonstrated significant efficacy in reducing blood pressure in patients with co-existing hypertension and hypercholesterolemia.
- Urapidil appears to be a safe and effective treatment option for this patient population.
- Further research may explore urapidil's long-term effects on cardiovascular outcomes.
Abstract:
The association of arterial hypertension and hyperlipidemia strikingly enhances prevalence, incidence and mortality of cardiovascular disease. In the light of recent evidence that some antihypertensive drugs with alpha-1 blocking properties reduce blood pressure (BP) and total cholesterol (chol), increasing chol content in the non-atherogenic high density lipoproteins (HDL-chol), the effects of urapidil, a peripheral alpha-1 adrenoceptor antagonist, with a central action component on BP and plasma lipids were evaluated in 49 mild, hypertensive patients with mild to moderately severe hypercholesterolemia (serum chol 220-320 mg/dl) for a 6 month period in a double-blind randomized study versus placebo. Five out of the 49 patients (3 on urapidil, 2 on placebo) discontinued treatment due to adverse side effects. Five patients on placebo did not meet protocol requirement of serum triglycerides < 350 mg/dl (3.95 mmol/L) and were only included in the BP efficacy assessment. The groups of urapidil and placebo were comparable for age (50 +/- 10 vs 49 +/- 7 years), body weight (72 +/- 9 vs 73 +/- 10 kg), sex (18M, 8F vs 14M, 9F) and mean arterial pressure (119.4 +/- 4 vs 119.7 +/- 4 mmHg). The actively treated group significantly decrease BP values from 159/99 +/- 13/2 to 152/90 +/- 23/8 mmHg, whilst no change was observed in the placebo group. Between group analysis showed a significant difference at the end of treatment (p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)